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Somatic Uniparental Isodisomy Explains
Multifocality of Glomuvenous Malformations
Mustapha Amyere,1,8 Virginie Aerts,1,8 Pascal Brouillard,1,8 Brendan A.S. McIntyre,1
Franc¸ois P. Duhoux,2 Michel Wassef,3 Odile Enjolras,4,9 John B. Mulliken,5 Olivier Devuyst,6
He´le`ne Antoine-Poirel,2 Laurence M. Boon,1,7 and Miikka Vikkula1,2,7,*
Inherited vascular malformations are commonly autosomal dominantly inherited with high, but incomplete, penetrance; they often
present as multiple lesions. We hypothesized that Knudson’s two-hit model could explain this multifocality and partial penetrance.
Weperformed a systematic analysis of inherited glomuvenousmalformations (GVMs) by usingmultiple approaches, including a sensitive
allele-specificpairwise SNP-chipmethod.Overall,we identified16 somaticmutations,most ofwhichwerenot intragenic butwere cases of
acquired uniparental isodisomy (aUPID) involving chromosome 1p. The breakpoint of each aUPID is located in an A- and T-rich, high-
DNA-flexibility region (1p13.1–1p12). This region corresponds to a possible new fragile site. Occurrences of these mutations render the
inherited glomulin variant in 1p22.1 homozygous in the affected tissues without loss of geneticmaterial. This finding demonstrates that
a double hit is needed to trigger formation of a GVM. It also suggests that somatic UPID, only detectable by sensitive pairwise analysis in
heterogeneous tissues, might be a common phenomenon in human cells. Thus, aUPID might play a role in the pathogenesis of various
nonmalignant disorders and might explain local impaired function and/or clinical variability. Furthermore, these data suggest that pair-
wise analysis of blood and tissue, even on heterogeneous tissue, can be used for localizing double-hit mutations in disease-causing genes.Introduction
Glomuvenous malformations (GVMs [MIM 601749]) are
hyperkeratotic bluish-purple cutaneous lesions and often
have a cobblestone-like appearance. GVMs account for
about 5% of venous anomalies referred to specialized
centers.1 On pathologic examination, GVMs are character-
ized by distended venous channels with flat endothelium
surrounded by variable numbers of rounded abnormal
mural glomus cells2 (Figure 1). These are abnormally differ-
entiated vascular smooth-muscle cells likely to be at the
origin of the lesion.3
GVM is transmitted as an autosomal-dominant trait
with variable expressivity and incomplete penetrance,
which is 92.7% at 20 years of age.3 Genetic studies have
localized the disease-causing mutations in glomulin
(GLMN) on the short arm of chromosome 1 (1p22.1).4–6
To date, 40 distinct germline mutations have been identi-
fied in 162 families3,7,8 (P.B., L.M.B., M.W., J.B.M., and
M.V., unpublished data). Among these, the most frequent
mutation (c.157_161del, formerly c.157delAAGAA; Table
S1, available online) was found in 72 families, and 86.5%
of families have one of 16 shared mutations. All mutations
are thought to cause loss of function. The inherited muta-
tions alone are not sufficient to explain the high pheno-
typic variability (number, size, and location of lesions),
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hit model for retinoblastoma (MIM 180200), i.e., the asso-
ciation between an inherited and a somatic mutation,
could be the explanation.9 Identifying such changes with
the use of lesional DNA for screening for exonic changes
has been relatively fruitless; there are only few reports in
some inherited vascular anomalies.10–13 To further investi-
gate the two-hit hypothesis, we used laser-capture micro-
dissection (LCM), cDNA analysis, sequencing, and paired
allele-specific SNP-chip copy-number analysis of fresh
GVM tissue.Material and Methods
Subject Recruitment
Informed consent was obtained from all the individuals prior to
their participation in the study, which was approved by the ethical
committee of the Medical Faculty at the Universite´ catholique
de Louvain (Brussels, Belgium). Twenty-eight GVM lesions and
corresponding blood samples were collected from 26 individuals
(Table 1). Additional paired blood and tissue samples were
collected from 41 individuals with other vascular anomalies.
Thirteen tissue samples of polycystic kidney disease (PKD [MIM
173900 and MIM 613095]) and their respective blood samples
were also collected and analyzed, given that somatic second hits
have been reported in some, but not all, such lesions. Moreover,
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Figure 1. Second-Hit Mutations in Six GVMs
Clinical photograph (left), hematoxylin and eosin histology (middle), and SNP-chip-based genotype and copy-number estimates for
chromosome 1 (right).
(A) GVM on left thigh of GVM71-12 has a partial deletion in 1p22.2–22.1, containing GLMN.
(B) Cheek lesion of GVM36-II-1. This tissue has a partial intragenic deletion (Table 1) yet no alteration in pairwise copy-number
analysis.
(C–F) Four representative GVM tissues from three patients with 1p aUPID: (C) right leg, (D) right foot, (E) abdomen, and (F) neck. Five
additional GVMs with a similar profile are shown in Figure S1.DNA and mRNA Samples
Vascular tissues were collected in liquid nitrogen immediately
after resection and were stored at 80C directly or after
optimal-cutting-temperature (OCT) embedding.We used the Pure-
gene DNA extraction kit (Gentra) for extraction of blood or tissual
DNA (five sections of 30 mm each) and Tripure (Roche) for purifica-
tion of total RNA.
mRNA-Based Screening
The SuperScript cDNA Synthesis Kit (Invitrogen, Life Technolo-
gies) was used for RT-PCR. The GLMN full-length transcript wasThe Americamplified and used as a template for 12 overlapping fragments
(0.4–1.0 kb). The amplicons were resolved on agarose gel for
the detection of abnormal bands. The entire mRNA was
sequenced for the samples screened (Table 1). In the case of
double sequence, amplicons were cloned into pCR2.1 (TOPO
TA Cloning Kit, Invitrogen, Life Technologies), and several clones
were sequenced.LCM
LCM was performed on a PALM Microlaser with the use of
5 mm cryosections stained with hematoxylin III (Gill) for thean Journal of Human Genetics 92, 188–196, February 7, 2013 189
Table 1. The 16 Somatic Second-Hit Mutations identified in 28 GVMs
Individual and Tissue Gender Inherited Mutationa Tissual RNA Glomus Cell DNA Arrays vs. Controls Pairwise Arrays
GVM43-II-1 M c.157_161del r.1141_1668delins1141–
100_1141–48
c.1141–42C>G NT NT
GVM107-10 M c.395–1G>A r.714_735del c.735þ1G>A NT NT
GVM36-II-1 M c.395–1G>A LOH WT allele LOH WT þ SNP i8d - -
GVM71-12 F c.107dup LOH WT allele LOH WT allele del1p22 NT
GVM7-810b F c.107dup LOH WT allele LOH WT þ SNP i8d - 1p aUPID
GVM22-100-legb F c.157_161del LOH WT allele LOH WT allele - 1p aUPID
GVM22-100-footb F c.157_161del LOH WT allele LOH WT allele - 1p aUPID
GVM67-11 M c.395–1G>C LOH WT allele NT - 1p aUPID
GVM16-IV-1c F c.743dup - LOH SNP i8d - 1p aUPID
GVM4-10b M c.554_558delinsG - NT - 1p aUPID
GVM24-10b F c.1711_1712del - - - 1p aUPID
GVM98-10 F c.157_161del NT NT - 1p aUPID
GVM150-10 F c.157_161del NT NT - 1p aUPID
GVM16-IV-2c F c.743dup NT - - 1p aUPID
GVM80-10 M c.422dup - - - 1p aUPID
GVM185 M c.422dup - - - 1p aUPID
GVM14-241b F c.1547C>G - - - -
GVM16-IV-2c F c.743dup NT - - -
GMV33-10b M c.108C>A NT NT - -
GVM67-1 M c.395–1G>C NT NT - -
GVM71-100 M c.107dup - NT - -
GVM90-101 M c.157_161del NT NT - -
GVM94-10-scre M c.422dup - - - -
GVM94-10-foot M c.422dup NT NT - -
GVM99-10 M c.157_161del NT NT - -
GVM100-10 F c.1179_1181del NT NT - -
GVM111-100 M c.36_37del NT NT - -
GVM127-11 F c.743dup NT NT - -
The following abbreviations are used: M, male; F, female; LOH, loss of heterozygosity; -, no alteration; NT, not tested; and aUPID, acquired uniparental isodisomy.
aMutations in GLMN (RefSeq NM_053274.2) were (re)named according to HGVS guidelines. RefSeq NG_009796 was used for the two mutations observed in
tissual RNA (GVM43-II-1 and GVM107-10).
bPedigree in Brouillard et al.3
cPedigree in Brouillard et al.6
drs1487540.
eFrom the scrotum.identification of nuclei. Several groups of glomus cells or dermal
cells were microdissected, 10–20 ml of DNA extraction buffer
(0.5 M EDTA pH 8, 1 M Tris pH 8, Tween 20, and 20 mg/ml
proteinase K) was added, and the mixture was incubated
overnight at 55C. Proteinase K was heat inactivated, and
2–3 ml was used in 50 ml PCR for 40 cycles. Amplicons were
analyzed either by denaturing high-performance liquid
chromatography (DHPLC) on a WAVE 3500 HS system (Trans-
genomic) or by sequencing on a CEQ2000 fluorescent cap-
illary sequencer (Beckman Coulter) or an ABI 3130xl (Life
Technologies).190 The American Journal of Human Genetics 92, 188–196, FebruaryAnalysis of Mutations
To predict the effects of intragenic mutations on splicing, we used
Human Splicing Finder software and MaxEntScan software for
short sequence motifs.Microarray Analyses
Molecular karyotyping was performed in all samples with Affyme-
trix Human Mapping 250K NspI or SNP6.0 SNP chips according
to the manufacturer’s (Affymetrix) instructions. In brief, total
genomic DNA was digested, and fragments were ligated to7, 2013
adaptors and amplified with a single primer. After purification of
the PCR products, amplicons were quantified, fragmented,
labeled, and hybridized on the array. Signal intensities were
measured with Affymetrix GeneChip Scanner 3000 7G.
Bioinformatic Analyses
Results were analyzed with Affymetrix Genotyping Console 4 and
with the Copy Number Analyzer for GeneChip (CNAG) 3.3.0.1 for
copy-number changes. Genotype-calling algorithms using the
Bayesian Robust Linear Model with Mahalanobis or the custom-
ized Expectation Maximization algorithm (Birdseed v.2) were
used for generating the genotypes for 250K or SNP6.0 chips,
respectively. In non-self-reference analysis, a hidden Markov
model (HMM) was used for identifying statistically significant
deviations in logarithmic ratios of signal intensities between
SNPs on the array. The reference data were drawn from a pool of
182 (250K array) or 69 (SNP6.0 array) arrays. Within this pool of
reference arrays, the signal-intensity SD values were ranked, and
the arrays with the smallest SD were used. Each array was refer-
enced to at least six other arrays of unrelated individuals. In pair-
wise analysis (comparing tissue- and blood-derived DNA), copy-
number variations in the two alleles were separately analyzed on
the basis of the genotyping information. Signal ratios were plotted
without the use of a logarithm. Copy-number status was derived
via algorithms based on the HMM.16,17
Fluorescence In Situ Hybridization
Fluorescence in situ hybridization (FISH) was performed as previ-
ously described.18 OCT-embedded frozen sections (5 mm) were
hybridized overnight with bacterial-artificial-chromosome probes
RP11-163M2 (1p22.1, covering the GLMN locus) and RP11-181G2
(control probe on 1p36.33). Control hybridizations were per-
formed with commercial probes Telomere 1q Spectrum Orange
and Telomere 7p Spectrum Green (Abbott Molecular).Results
No GLMN Second Hit Detected in DNA from GVMs
To identify somatic mutations in GLMN (RefSeq accession
number NM_053274.2), we isolated genomic DNA from 28
resected GVM specimens (26 individuals, Table 1). The in-
herited mutations were already known for most of the
individuals3,7,19 (P.B., L.M.B., M.W., J.B.M., and M.V.,
unpublished data). We screened the 19 exons and their
splice sites of GLMN. This whole-tissue approach did not
reveal any somatic changes in GLMN but uncovered the
heterozygous inherited mutations that were also present
in blood-derived DNA (Table 1).
IntragenicGLMN Second Hits Detected inmRNA from
GVMs
To increase sensitivity of our screens, we extracted total
RNA from a set of 14 frozen GVMs (Table 1). The GLMN
transcripts were screened in 12 overlapping fragments.
Besides the allele that carried the known inherited muta-
tion of family GVM43-II-1, the amplicon covering the
full-length cDNA had a shorter product. This allele was
wild-type with regard to the germline mutation but had
a deletion of exons 13–18 and an insertion of 54 bp fromThe Americintron 12 (r.1141_1668delins1141–100_1141–48). Using
LCM tissue, we discovered in the middle of intron 12
a substitution (c.1141–42C>G) causing a new strong splice
site leading to the deletion (Table 1).
For GVM107-10, we found an allele with a deletion of
the first eight nucleotides of exon 6 (c.395_402del). This
most likely resulted from the inherited splice-site mutation
in the last nucleotide of intron 5 (Table 1). The second
allele had a deletion of the last 22 nucleotides of exon 7
(r.714_735del). In microdissected tissue, we detected
a substitution of the first nucleotide of intron 7
(c.735þ1G>A). This destroyed the canonical splice site.
An alternative consensus site lay 22 nucleotides upstream
(Table 1), corresponding to the deletion observed in
mRNA.
For six other tissues, we detected a loss or a significant
decrease in expression of the allele that did not carry the
inherited mutation (Table 1), suggesting a somatic muta-
tion in regulatory elements, epigenetic modification,
and/ or loss of heterozygosity (LOH). No genetic mutation
was found in the six other lesions.
LOH Detected in DNA from Microdissected Tissues
To study LOH in GVMs, we extracted genomic DNA from
microdissected tissues of ten lesions (Table 1). Six samples
demonstrated LOH: GVM7-810, GVM22-100-leg, GVM22-
100-foot, GVM36-II-1, and GVM71-12 were homozygous
for the respective inherited mutation, and GVM7-810,
GVM16-IV-1, and GVM36-II-1 lost heterozygosity such
that they were missing one allele for a SNP (rs1487540)
in intron 8 of GLMN. No mutation was detected in the
other four samples tested. These results suggest the pres-
ence of larger genomic alterations encompassing, at least
partially, the GLMN locus.
aUPID Detected in GVMs by Pairwise Copy-Number
Analysis
We used Affymetrix SNP-chip arrays on DNAs extracted
from a series of 26 GVMs to define the extent of the LOH
detected in microdissected glomus cells and to detect addi-
tional tissues with LOH. The hybridization signals were
first compared to those of a large reference set of 260 unaf-
fected and unrelated blood samples. In GVM71-12, we de-
tected an interstitial deletion in 1p22.2–22.1 (the region
containing GLMN) and no other chromosomal abnor-
mality (Figure 1A and Table 1). Within the deleted region,
we identified a large number of heterozygous SNPs with an
average copy-number estimate of 1.7, which indicates
tissue heterogeneity (Figure 1A). In all other GVMs, the
overall copy number was equal to 2, and there was no
LOH or other variation (data not shown).
Next, we compared each GVM to its respective blood-
derived DNA in a pairwise manner. In GVM36-II-1, in
which microdissected tissue was homozygous for the in-
herited GLMN mutation and the intronic SNP rs1487540,
no chromosomal aberration was found (Figure 1B and
Table 1). This indicates that the size of the LOH was belowan Journal of Human Genetics 92, 188–196, February 7, 2013 191
Table 2. Diploid Glomus Cells in Three GVM Lesions out of 100
Nuclei Analyzed by FISH Locus-Specific Probe
Individual and Tissue
Percentage of Diploid Glomus Cells
1p22.1a 1p36.33b 1qterc 7pterd
GVM22-100-leg 93% 93% 94% 94%
GVM22-100-foot 93% 95% 94% 94%
GVM98-10 96% 96% 92% 92%
Average 94% 95% 93% 93%
aRP11-163M2.
bRP11-181G12.
cTelomere 1q Spectrum Orange.
dTelomere 7p Spectrum Green.25 kb, the resolution of the 250K chip array used. All other
samples also showed two copies of each chromosome
(Figures 1C–1F and Figures S1A–S1E). In 12 GVMs, the
short arm of chromosome 1 had significantly increased
genotypic discordance between lesional DNA and the cor-
responding lymphocytic DNA (Figures 1C–1F and Figures
S1A–S1E). Moreover, when we compared the copy-number
status of each allele separately by pairwise analysis of blood
and tissue, we observed a statistically significant diver-
gence. This was accompanied by increased LOH on 1p.
This copy-neutral LOH suggests that the loss of one allele
is compensated by the gain of the other allele—evidence
of acquired uniparental isodisomy (aUPID)20,21 (Figures
1C–1F, Figures S1A–S1E, and Table 1). The fact that 1p
remained heterozygous in all tissues indicates that aUPID
is present only in a subpopulation of cells. Tissual hetero-
geneity increases the difficulty in detecting aUPID (Figures
1C–1F and Figures S1A–S1E).
No Aneuploidy Detected in GVMs
To confirm the presence of two copies of the short arm of
chromosome 1 in GVMs, we analyzed three different
lesions by FISH (Table 2 and Figure S2). In all three lesions,
the number of cells showing two hybridization signals for
the two probes in 1p was identical to that of the two
control probes on 1q and 7p, i.e., 93–95 out of 100 nuclei
counted in resected glomus cells.
Break Points of Identified aUPID Localized to
1p13.1–1p12
To map the breakpoints of each case of aUPID, we
combined the LOH and pairwise copy-number data. Using
a gliding window set to ten SNPs, we scanned the chromo-
some 1p pericentromeric area from centromere to telo-
mere, and we considered as the breakpoint the region in
which we started to detect a deviation between the esti-
mated copy number of an allele in tissue-blood pairs.
This corresponded to the starting-point LOH. We found
that all identified breakpoints were located in a ~2.94 Mb
region containing ~60% A and T at 1p13.1–1p12 (Table 3).
This region contained multiple tandem repeats of A and T,
illustrated by the identification of tandemly repeated192 The American Journal of Human Genetics 92, 188–196, Februarystructures in DNA sequences (mreps software; Table S1).
With the resolution of the technique used, it is impossible
to state how many independent sequences and/or sites
were involved.1p aUPID Not Found in a Series of Other Tissues
To determine whether somatic 1p aUPID is specific
to GVMs or is a common somatic event, we analyzed 54
other blood-tissue pairs. These included 41 vascular anom-
alies, including infantile hemangiomas (MIM 602089)
(n ¼ 20), cutaneomucosal-venous malformations (MIM
600195) (n ¼ 4), capillary malformations (CMAVMs
[MIM 608354]) (n ¼ 3), and lymphatic malformations
(n ¼ 14), as well as tissues from polycystic kidneys (n ¼
13). None of the 54 samples showed evidence of somatic
1p aUPID (data not shown).Second Hits Enriched in Glomus Cells
Our difficulty in detecting second hits in GVMs suggested
cellular heterogeneity in the resected lesions (illustrated in
Figure S3). Because the resected tissue GVM22-100-leg con-
tained overlying skin, we laser captured dermal cells
(Figure 2A) and abnormal cells (Figure 2B) for separate
DNA analyses. Amplification of a fragment overlapping
the inherited mutation (c.157_161del) confirmed that
the abnormal cells demonstrated LOH, given that they
predominantly contained the allele harboring the germ-
line mutation, whereas dermal cells, whole tissue, and
blood were all heterozygous (Figure 2C).Discussion
Phenotypic variability in individuals with GVMs, even in
those who have the same inherited mutation, suggests
that an additional genetic event might trigger the forma-
tion of a lesion. Previously, we proposed that this event
might be a somatic second hit and identified one such
mutation in one GVM specimen. Herein, we screened 28
additional GVMs and identified a second hit in 16 lesions
(Table 1); these included two (11.75%) intragenic point
mutations, two (11.75%) intragenic deletions, and one
(5.9%) interstitial 1p22.2–22.1 deletion containing
GLMN. Unexpectedly, the majority of the mutations we
identified (12 mutations; 70.6%) were cases of 1p aUPID.
These data suggest that somatic second hits are necessary
for the formation of GVMs and explain the variable pheno-
type and incomplete penetrance observed. Moreover,
heterozygous glomulin knockout mice are phenotypically
normal, but homozygous glomulin knockout mice die in
utero (unpublished data). Taken together, these data
support the somatic second-hit model for GVM formation.
aUPID discovered in GVMs results in duplication of the
mutant allele and loss of the wild-type without causing
quantitative loss of other genes. Such a mechanism has
been described in cancerous tissues, but not in noncan-
cerous Mendelian disorders. Indeed, if LOH were caused7, 2013
Table 3. aUPID Breakpoint Boundaries Identified on 1p in 12 GVMs
Individual and Tissue
Telomeric
SNP ID
Centromeric
SNP ID
Breakpoint Region
Limit (bp) Size (kb) Location
Affymetrix Array
Used
GVM80-10 rs6428670 rs10494190 117,168,713–117,194,463 25.8 1p13.1 SNP6.0
GVM98-10 rs12087175 rs12410934 117,636,914–117,656,082 19.2 1p13.1 SNP6.0
GVM150-10 rs167662 rs1975283 117,929,096–117,944,081 15.0 1p12 SNP6.0
GVM7-810a rs12404666 rs1146342 118,733,848–118,784,700 50.9 1p12 SNP6.0
GVM16-IV-2b rs1779430 rs12027986 119,262,320–119,372,788 110.5 1p12 250K
GVM185 rs17023224 rs6676180 119,434,378–119,584,746 150.4 1p12 250K
GVM16-IV-1b rs17186115 rs3753263 119,631,749–119,711,372 79.6 1p12 250K
GVM24-10a rs860792 rs1819698 119,693,142–119,767,042 73.9 1p12 250K
GVM67-11 rs3753263 rs1417608 119,711,372–119,779,356 68.0 1p12 250K
GVM4-10a rs10489811 rs3949342 119,784,626–119,816,321 31.7 1p12 250K
GVM22-100-lega rs17023814 rs539799 119,897,445–120,009,995 112.6 1p12 250K
GVM22-100-foota rs920513 rs2289459 120,074,129–120,113,001 38.9 1p12 250K
aPedigree in Brouillard et al.3
bPedigree in Brouillard et al.6by the deletion of 1p, the result would most likely be
progression to malignancy because of the loss of several
tumor-suppressor genes that reside in 1p. This finding
suggests that aUPID might be involved in various other
disorders in which lesions are localized, for example,
vascular disorders such as hereditary hemorrhagic telangi-
ectasia (HHT [MIM 187300]), cerebral cavernous malfor-
mations (CCMs [MIM 116860]), and CMAVMs, as well as
other disorders, such as PKD. It might also explain why
second-hit screens (focusing on intragenic mutations)
have often been unrewarding. We reported one intragenicFigure 2. Lack of GLMN Is Restricted to the Lesion
(A–C) Amplification of a 95 bp fragment overlapping the inherited
mutation (c.157_161del) of GVM22-100 (A) shows enrichment of
the mutant allele in microdissected glomus cells (B) compared to
overlying dermal cells (C), whole GVM, and blood. The lack of
GLMN is restricted to glomus cells.
The Americsomatic second hit in a mucocutaneous-venous malforma-
tion10 and one in a GVM,3 and others have found five
somatic second hits in CCMs.11–13,22 Screens in HHT
have been fruitless, leading to a strong debate regarding
the second-hit mechanism as being the explanation for
the localized vascular lesions in HHT. Nevertheless, murine
studies support the two-hit mechanism in HHT and
CCMs.23–25
Mitotic recombination occurs at a higher frequency in
centromeres and telomeres than in the rest of the chromo-
somes.26 Aneuploidy is a direct consequence of chromo-
somal-segregation errors in mitosis.27 In the 12 GVMs
with aUPID, the breakpoints reside close to each other
(according to the resolution of the SNP chips) near the
centromere at 1p13.1–1p12. This region is rich in A and
T sequences. (Table S2). Such A- and T-rich regions have
been suggested to be associated with common aphidicolin
fragile sites.28 The 1p13.1–1p12 region does not contain
a known fragile site. Another possibility is break-induced
recombination. The underlying haploinsufficiency in glo-
mulin might play a role in these mechanisms.
A number of studies have recorded an accumulation of
somatic mutations in human tissues and support the idea
that the mutation rate per cell division is much greater in
somatic cells than in germline cells.29 The human somatic
mutational rate has been estimated to be less than one
mutation per megabase per generation30,31 but as high as
17.7 mutations per megabase throughout the genome of
a pulmonary tumor.32 Single-nucleotide substitutions are
~25 times more common than all other mutations, and
deletions are approximately three times more common
than insertions, whereas complex mutations are very
rare.30 In light of these data, we expected to detect
single-nucleotide substitutions. There are no accurate esti-
mates of the frequency of mitotic aUPID— the mostan Journal of Human Genetics 92, 188–196, February 7, 2013 193
common somatic mutation detected in our study—in
human cells.
The frequency of germline UPD as the result of impaired
meiotic allelic disjunction is estimatedat less than2%in the
human genome.33 Therefore, for any chromosome, UPD
is expected in only 1/3,500 births.34 aUPID occurs as a post-
fertilization mitotic recombination event. It has been
described in cancers.35 Therefore, aUPID is an attractive
model to explain localized dysfunction in various diseases.
In the 13 PKD tissues analyzed, no aUPID of 1p or the chro-
mosomes containing the genes associatedwith PKD types 1
an 2 was identified. However, an individual with neonatal
renal cystic disease was reported to be homozygous for
a missense mutation due to UPD in PKD type 2.15,36–38
The rate of meiotic, as well asmitotic, recombination has
been calculated to be twice as high in females as inmales.39
Accordingly, in a series of 12 cases of aUPID, one would
expect to see eight to nine in females and three to four
in males. In our series, 7 of the 12 GVMs with 1p aUPID
occurred in females. There was no difference in transmis-
sion of the inherited mutation between paternal and
maternal alleles in individuals with lesions with aUPID.
Cellular heterogeneity makes it difficult to determine
somatic changes in GVMs, as well as most other disorders.
Resected GVMs are composed of endothelial cells, vascular
smooth-muscle cells, glomus cells, fibroblasts, keratino-
cytes, and blood cells (Figure 2 and Figure S3). This diver-
sity complicates detection of somatic mutations in whole
tissues, especially at the genomic DNA level, because
normal cells canmask low-number mutant cells. To bypass
this obstacle, we used both cDNA analysis (to screenGLMN
exons only in cells expressing it) and DNA analysis on
microdissected lesions. In addition, allele-specific pairwise
analyses with SNP chips allowed detection of aUPID even
in heterogeneous whole tissue. Our findings underscore
the presence of a second-hit mutation that is located in
a GVM and that renders it devoid of glomulin. Thus, in
a particular individual, the timing of the second hit’s
occurrence most likely influences the number of affected
cells in the lesion and thus the size of the lesion. This
proposal is supported by the fact that the two distant resec-
tions of the same lesion of GVM22 (that of the right leg
and that of the right foot; Figures 1C and 1D) showed
the same somatic mutation (i.e., 1p aUPID).
In conclusion, this study demonstrates that somatic
second hits explain the wide phenotypic variability of
GVMs with regard to size, number, and localization of
lesions. These somatic mutations eliminate GLMN locally,
most commonly via homozygosity for the inherited loss-
of-function mutation due to aUPID. GVMs exemplify
aUPID in a noncancerous disorder and suggest a wider
implication for aUPID in human disease.Supplemental Data
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